TRK-IN-29
TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKAG595R, TRKAF589L, TRKAG667C, TRKA and TRKC respectively) . TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties[1].
Product Specifications
UNSPSC
12352005
Target
Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/trk-in-29.html
Smiles
C[C@H](C1=CC(F)=CC=C1OCC(F)F)NC2=CC3=C(NN=C3N4N=CN=C4)C=C2
Molecular Formula
C19H17F3N6O
Molecular Weight
402.37
References & Citations
[1]Qiaohua Qin, et al. Discovery of novel indazole derivatives as second-generation TRK inhibitors. European Journal of Medicinal Chemistry. Available online 1 July 2024, 116640, et al.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
